You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.
An analysis by Science finds that many institutes have not uploaded results to ClinicalTrials.gov within the one-year deadline.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
In an editorial, the New York Times examines issues the new US Food and Drug Administration commissioner is to face.
The group wants the agency to allow labs to discuss gene-drug relationships with "adequate evidence" in test reports and hold a public meeting.
Despite the availability of more precision therapies and complex biomarker tests, systemic gaps and lack of physician education continued to hinder access.
The drug is approved as a maintenance treatment for platinum-responsive metastatic pancreatic cancer patients with germline BRCA1/2 mutations.
The budget for fiscal year 2020 includes increases for each of the NIH's institutes and centers, as well as the FDA and the NSF.
The LRT BAL panel detects a wide spectrum of clinically relevant causative agents, such as atypical pathogens and antibiotic resistance markers.
In addition to developing standards for proteomics, metabolomics, and other kinds of data, DNAnexus will develop tools to help reviewers quickly and easily assess analysis pipelines.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.